Gene-environment interplay in schizopsychotic disorders

被引:0
作者
Tomas Palomo
Trevor Archer
Richard M. Kostrzewa
Richard J. Beninger
机构
[1] Hospital Universitario,Servicio Psiquiátrico
[2] University of Göteborg,Dept. Psychology
[3] Quillen College of Medicine,Dept. Pharmacology
[4] East Tennessee State Univ.,Depts. Psychology and Psychiatry
[5] Queen’s Univ.,undefined
来源
Neurotoxicity Research | 2004年 / 6卷
关键词
Dopamine; GABA; Genetics; Glutamate; Parvalbumin; PKA; Schizophrenia; Signaling Molecules; Stress;
D O I
暂无
中图分类号
学科分类号
摘要
Genetic studies have sought to identify subtypes or endophenotypes of schizophrenia in an effort to improve the reliability of findings. A number of chromosomal regions or genes have now been shown to have had replicated linkage to schizophrenia susceptibility. Molecules involved in neurodevelopment or neurotransmitter function are coded by many of the genes that have been implicated in schizophrenia. Studies of neurotransmitter function have identified, among others, a possible role for GABA, glutamate and dopamine in animal models of schizophrenia. GABA neurons that co-express the calcium binding protein parvalbumin have been implicated as have glutamatergic metabotropic receptors and dopamine D3 receptors. Stress influences glutamate and dopamine providing another environmental factor that may interact with the influence of genes on neurotransmitter function. Neurotransmitter interactions include influences on signaling molecules and these too have been implicated in forms of learning thought to be affected in schizophrenia. Results continue to unravel the interplay of genes and environment in the etiology of schizophrenia and other psychotic disorders.
引用
收藏
页码:1 / 9
页数:8
相关论文
共 302 条
[21]  
Sham P(2004)The genetic relationship of personality to major depression and schizophrenia Neurotoxicity Res. 6 43-50
[22]  
Kerwin R(2002)Nerotocism, major depression ands gender: a population-based twin study Psychol. Med. 32 710-728
[23]  
Bagley J(1984)The effects of phencyclidine and Eur. J. Pharmacol. 104 287-293
[24]  
Moghaddam B(1985)-allynomethazocine on midbrain dopamine neuronal activity Eur. J. Pharmacol. 116 1-9
[25]  
Beasley CL(1990)Phencyclidine binding sites in the nucleus accumbens and phencyclidine-induced hyperactivity are decreased following lesions of the mesolimbic dopamine system Brain Res. Bull. 25 485-498
[26]  
Reynolds GP(2001)Startle response models of sensorimotor gating and habituation deficits in schizophrenia Psychopharmacology 156 117-154
[27]  
Benes FM(1991)Pharmacological studies of prepulse inhibition models of senso-rimotor gating deficits in schizophrenia: a decade in review Am. J. Psychiatry 148 1301-1308
[28]  
McSparren J(1999)Recent advances in the phencycli-dine model of schizophrenia Neuropsychopharmacol 20 201-225
[29]  
Bird ED(1997)The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 17 92-99
[30]  
SanGiovanni JP(2001)Sub-chronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat Science 294 1030-1038